CLOs on the Move


 
  • Number of Employees:
  • Annual Revenue:

  • ,

Executives

Name Title Contact Details

Similar Companies

Aspire General Insurance

Aspire General Insurance is a California-based insurance provider that specializes in private passenger auto insurance. Founded in 2012, the company operates in Arizona, California, and Michigan, offering services in both English and Spanish. Aspire has an AM Best rating of B++ (Good) with a Stable outlook, indicating its financial stability. The company focuses on liability and physical damage coverage for private passenger vehicles. It provides 24/7 claims reporting and in-house processing, along with online and mobile tools for policy management, payments, and document access. Aspire offers flexible payment options, including low down payments and installment plans. Their customer support features bilingual call centers and automated solutions for policy updates and claims tracking, ensuring a responsive service experience.

DUAL North America

DUAL North America is a prominent independent underwriting organization based in the United States, part of the global DUAL Group. Established in 2013, it has become a leading program administrator in the insurance sector. The company operates under the Howden-owned DUAL Group, which is recognized as one of the largest managing general agents worldwide, with a presence in 21 countries and over $3.5 billion in gross written premium. The company specializes in expert underwriting solutions across various insurance lines, including commercial property, casualty, financial lines, and surety. DUAL North America offers more than 40 unique products tailored to meet diverse client needs. It also features a robust online platform that enables appointed producers to quote, bind policies, and manage documents digitally. With a network of over 11,000 brokers globally, DUAL North America serves a wide range of clients, from small businesses to large fleets, particularly in regions like California and Texas.

RKL LLP

RKL is a provider of internal audit, risk management and investment advisory services for credit unions, manufacturing and distribution industries.

Valent Partners

Valent Partners are an integrated team of strategists, business leaders and technologists obsessed with helping our clients reach new heights. We approach each situation through a holistic business and technology lens, advising on and delivering solutions that help your organization adapt ahead of your competition. You have a goal. Well get you there. If your organization is interested in finding ways that technology can improve your performance, profitability, and growth, we can help. Contact Valent Partners today to arrange a consultation on the challenges you face. Your Digital Journey begins here.

IMUNON

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.